Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma Clinical Trial
Official title:
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
| Verified date | March 2022 |
| Source | Novartis |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.
| Status | Completed |
| Enrollment | 283 |
| Est. completion date | March 17, 2021 |
| Est. primary completion date | March 17, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Patients with advanced/metastatic cancer, with measurable disease as determined by RECIST version 1.1, who have progressed despite standard therapy or are intolerant to standard therapy, and for whom no effective therapy is available. Patients must fit into one of the following groups: - Colorectal cancer (CRC) (not mismatch repair deficient by local assay including PCR and/or immunohistochemistry) - Non-small cell lung cancer (NSCLC) (adenocarcinoma) - Triple Negative Breast Cancer (TNBC) (D - ECOG Performance Status = 2 - Patient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at baseline, and again during therapy on this study. - Prior therapy with PD-1/PDL-1 inhibitors is allowed provided any toxicity attributed to prior PD-1- or PD-L1-directed therapy did not lead to discontinuation of therapy. - Written informed consent must be obtained prior to any screening procedures other than procedures performed as part of standard of care. Exclusion Criteria: - Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local CNS-directed therapy, or increasing doses of corticosteroids within the prior 2 weeks. - History of severe hypersensitivity reactions to other monoclonal antibodies. - Out of range laboratory values for measures of hepatic and renal function, electrolytes and blood counts - Impaired cardiac function or clinically significant cardiac disease. - Patients with active, known or suspected autoimmune disease. - Human Immunodeficiency Virus infection at screening. - Escalation part: Active Hepatitis B (HBV) or Hepatitis C (HCV) virus infection at screening. Expansion part: Patients with active HBV or HCV are excluded, excepting those patients undergoing treatment for HBV or HCV. - Malignant disease, other than that being treated in this study. - Recent systemic anti-cancer therapy - Active infection requiring systemic antibiotic therapy. - Patients requiring chronic treatment with systemic steroid therapy, other than replacement dose steroids in the setting of adrenal insufficiency or treatment with low, stable dose of steroid (<10mg/ day prednisone or equivalent) for stable CNS metastatic disease. - Patients receiving systemic treatment with any immunosuppressive medication, excepting the above - Use of any live vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) within 4 weeks of initiation of study treatment. - Participation in an interventional, investigational study within 2 weeks of the first dose of study treatment. - Presence of = CTCAE grade 2 toxicity (except alopecia and ototoxicity, which are excluded if = CTCAE grade 3) due to prior cancer therapy. - Recent use of hematopoietic colony-stimulating growth factors (e.g. G-CSF, GMCSF, M-CSF) Additional exclusion criteria for Combination arm PDR001+canakinumab and single-agent canakinumab - Patients with tuberculosis (TB). Note: Patient with latent TB may be eligible based on the investigator's benefit-risk assessment. - Patients who have been infected with HBV or HCV including those with inactive disease. Additional exclusion criteria for Combination arm PDR001+CJM112 - Patients with TB. Note: Patient with latent TB may be eligible based on the investigator's benefit-risk assessment. - Patients with history of and/or active inflammatory bowel disease. - Active skin or soft tissue infection including cellulitis, erysipelas, impetigo, furuncle,carbuncle, abscess, or fasciitis. - Active candida infection, including mucocutaneous infection or history of invasive candidiasis. Additional exclusion criteria for Combination arm PDR001+trametinib - Patients with history of retinal vein oclusion. - Patients with history of interstitial lung disease or pneumonitis. - Patients with cardiomyopathy and/or LVEF < LLN. - Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of oral combination partners. - Hemoglobin (Hgb) < 9 g/dL without growth factor or transfusion support - Women of child-bearing potential using hormonal contraception, unless an additional contraception method is also used according to the Mekinist® label. Additional exclusion criteria for Combination arm PDR001+EGF816 - NSCLC patients with EGFR mutant tumors. - Strong inhibitors and strong inducers of CYP3A4 should not be used concomitantly. - Patients with history of interstitial lung disease. - Patients who have been infected with HBV or HCV including those with inactive disease. - Impairment of gastrointestinal function or GI disease that may significantly alter the absorption of oral combination partners - Patients cannot have received radiotherapy to lung fields within 6 months of study treatment start. |
| Country | Name | City | State |
|---|---|---|---|
| Belgium | Novartis Investigative Site | Brussels | |
| Belgium | Novartis Investigative Site | Wilrijk | |
| Canada | Novartis Investigative Site | Montreal | Quebec |
| Canada | Novartis Investigative Site | Toronto | Ontario |
| France | Novartis Investigative Site | Lyon Cedex | |
| France | Novartis Investigative Site | Paris | |
| France | Novartis Investigative Site | Toulouse Cedex 9 | |
| France | Novartis Investigative Site | Villejuif Cedex | |
| Israel | Novartis Investigative Site | Tel Aviv | |
| Italy | Novartis Investigative Site | Milano | MI |
| Italy | Novartis Investigative Site | Rozzano | MI |
| Singapore | Novartis Investigative Site | Singapore | |
| Singapore | Novartis Investigative Site | Singapore | |
| Spain | Novartis Investigative Site | Barcelona | Catalunya |
| Spain | Novartis Investigative Site | Hospitalet de LLobregat | Catalunya |
| Spain | Novartis Investigative Site | Madrid | |
| Spain | Novartis Investigative Site | Madrid | |
| Taiwan | Novartis Investigative Site | Tainan | |
| Taiwan | Novartis Investigative Site | Taoyuan | |
| United States | Sidney Kimmel Comprehensive Cancer Center SC-3 | Baltimore | Maryland |
| United States | Dana Farber Cancer Center | Boston | Massachusetts |
| United States | University of Texas MD Anderson Cancer Center | Houston | Texas |
| United States | Sarah Cannon Research Institute | Nashville | Tennessee |
| Lead Sponsor | Collaborator |
|---|---|
| Novartis Pharmaceuticals |
United States, Belgium, Canada, France, Israel, Italy, Singapore, Spain, Taiwan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Frequency of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety | Throughout the study at every visit, an average of 1 year | ||
| Primary | Changes between baseline and post-baseline laboratory parameters and vital signs. | Baseline and throughout the study at every visit, an average of 1 year | ||
| Primary | Incidence of dose limiting toxicities (DLTs) of treatment (Escalation only) | During the first two cycles; Cycle = 28 days | ||
| Primary | Frequency of dose interruptions | Throughout the study at every visit, an average of 1 year | ||
| Primary | Dose intensities | Throughout the study at every visit, an average of 1 year | ||
| Primary | Severity of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety | Throughout the study at every visit, an average of 1 year | ||
| Primary | Frequency of dose reductions | Throughout the study at every visit, an average of 1 year | ||
| Secondary | Key secondary: Histopathology of tumor infiltrating lymphocytes (TILs) | Baseline and approximately after 2 cycles of treatment and at disease progression; Cycle = 28 days | ||
| Secondary | Changes from baseline in electrocardiogram (ECG) parameters | Baseline and end of treatment, an average of 1 year | ||
| Secondary | Best overall response (BOR) | T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2 | T1: Every 2 cycles until the start of T2. T2: Every 2 cycles until cycle 3 and then every 3 cycles until PD; cycle = 28 days | |
| Secondary | Progression free survival (PFS) per irRC and RECIST v1.1 | T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2 | T1: Every 2 cycles until the start of T2. T2: Every 2 cycles until cycle 3 and then every 3 cycles until PD; cycle = 28 days | |
| Secondary | Treatment Free Survival (TFS) | T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2 | T1: Every 2 cycles until the start of T2. T2: Every 2 cycles until cycle 3 and then every 3 cycles until PD; cycle = 28 days | |
| Secondary | Presence and/or concentration of anti-PDR001 antibodies. | T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2 | Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year) | |
| Secondary | Serum concentration of PDR001, canakinumab, CJM112 | T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2 | Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year) | |
| Secondary | Plasma concentrations of trametinib and EGF816 | T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2 | Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year) | |
| Secondary | Key secondary: Histopathology of myeloid cell infiltrate by IHC (such as CD8, FoxP3 and myeloid markers as appropriate). | Baseline and approximately after 3 cycles of treatment and at disease progression; cycle = 28 days | ||
| Secondary | PK parameters (Eg. TMax) of EGF816 | T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2 | Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year) | |
| Secondary | PK parameters (Eg. TMax) of trametinib | T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2 | Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year) | |
| Secondary | PK parameter (Eg. TMax) of PDR001 | T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2 | Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year) | |
| Secondary | PK parameters (Eg. TMax) of canakinumab | T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2 | Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year) | |
| Secondary | PK parameters (Eg. TMax) of CJM112 | T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2 | Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year) | |
| Secondary | Presence and/or concentration of anti-canakinumab antibodies. | T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2 | Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year) | |
| Secondary | Presence and/or concentration of anti-CJM112 antibodies. | T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2 | Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year) |